5-HT2A receptor density is decreased in the at-risk mental state

Rationale Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS). Objective To study the cerebral 5-HT 2A receptor (5-HT 2A R) in the ARMS with [ 18 F]altanserin positron emission to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychopharmacologia 2008-01, Vol.195 (4), p.579-590
Hauptverfasser: Hurlemann, René, Matusch, Andreas, Kuhn, Kai-Uwe, Berning, Julia, Elmenhorst, David, Winz, Oliver, Kolsch, Heike, Zilles, Karl, Wagner, Michael, Maier, Wolfgang, Bauer, Andreas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 590
container_issue 4
container_start_page 579
container_title Psychopharmacologia
container_volume 195
creator Hurlemann, René
Matusch, Andreas
Kuhn, Kai-Uwe
Berning, Julia
Elmenhorst, David
Winz, Oliver
Kolsch, Heike
Zilles, Karl
Wagner, Michael
Maier, Wolfgang
Bauer, Andreas
description Rationale Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS). Objective To study the cerebral 5-HT 2A receptor (5-HT 2A R) in the ARMS with [ 18 F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm. Materials and methods We quantified the spatial distribution of 5-HT 2A R binding potential (BP 1 ′) in never-medicated subjects assigned to early ( n  = 6) and late ( n  = 8) prodromal states of schizophrenia relative to healthy controls ( n  = 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT 2A R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP 1 ′ due to between-group differences in genotype distributions. Results Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP 1 ′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP 1 ′ was present in subjects who subsequently converted to first-episode psychosis ( n  = 5), but absent in non-converters ( n  = 9). Between-group differences were not confounded by a differential distribution of SNP genotypes. Conclusion These results suggest a progressive reduction of cortical 5-HT 2A R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT 2A R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia.
doi_str_mv 10.1007/s00213-007-0921-x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70099863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70099863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</originalsourceid><addsrcrecordid>eNp1kMtKBDEQRYMoOj4-wI00gu6ieXYnO0V8geBG1yHJVGtrT_eYyoD-vRlmYEAwm9yizq0qLiHHnF1wxppLZExwSYukzApOv7fIhCspqGCN2CYTxqSkkmuzR_YRP1h5yqhdsscbY23xTsiVpg8v4rpKEGGex1RNYcAu_1QdFhkTeIRp1Q1VfofKZ5o6_KxmMGTfV5h9hkOy0_oe4Wj9H5DXu9uXmwf69Hz_eHP9RKOqdaZKBW1aJWIMtRbT1sQopNE6RO2FbxoNNjRBBq9VlEbF2stSKKFE8EGClwfkfDV3nsavBWB2sw4j9L0fYFygaxiz1tSygKd_wI9xkYZymxPc2IbXhhWIr6CYRsQErZunbubTj-PMLbN1q2zdUi6zdd_Fc7IevAgzmG4c6zALcLYGPEbft8kPscMNZ62qlV4uFysOS2t4g7S58P_tvwiWj9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218971680</pqid></control><display><type>article</type><title>5-HT2A receptor density is decreased in the at-risk mental state</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Hurlemann, René ; Matusch, Andreas ; Kuhn, Kai-Uwe ; Berning, Julia ; Elmenhorst, David ; Winz, Oliver ; Kolsch, Heike ; Zilles, Karl ; Wagner, Michael ; Maier, Wolfgang ; Bauer, Andreas</creator><creatorcontrib>Hurlemann, René ; Matusch, Andreas ; Kuhn, Kai-Uwe ; Berning, Julia ; Elmenhorst, David ; Winz, Oliver ; Kolsch, Heike ; Zilles, Karl ; Wagner, Michael ; Maier, Wolfgang ; Bauer, Andreas</creatorcontrib><description>Rationale Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS). Objective To study the cerebral 5-HT 2A receptor (5-HT 2A R) in the ARMS with [ 18 F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm. Materials and methods We quantified the spatial distribution of 5-HT 2A R binding potential (BP 1 ′) in never-medicated subjects assigned to early ( n  = 6) and late ( n  = 8) prodromal states of schizophrenia relative to healthy controls ( n  = 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT 2A R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP 1 ′ due to between-group differences in genotype distributions. Results Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP 1 ′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP 1 ′ was present in subjects who subsequently converted to first-episode psychosis ( n  = 5), but absent in non-converters ( n  = 9). Between-group differences were not confounded by a differential distribution of SNP genotypes. Conclusion These results suggest a progressive reduction of cortical 5-HT 2A R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT 2A R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-007-0921-x</identifier><identifier>PMID: 17899021</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Adult and adolescent clinical studies ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Brain - diagnostic imaging ; Brain Mapping ; Cerebral Cortex - diagnostic imaging ; Dominance, Cerebral - physiology ; Early Diagnosis ; Female ; Fluorine Radioisotopes ; Genetic Markers - genetics ; Genetic Predisposition to Disease ; Genotype ; Genotype &amp; phenotype ; Humans ; Ketanserin - analogs &amp; derivatives ; Male ; Medical sciences ; Neurosciences ; Neurotransmitters ; Original Investigation ; Pharmacology ; Pharmacology/Toxicology ; Positron-Emission Tomography ; Psychiatric Status Rating Scales ; Psychiatry ; Psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Receptor, Serotonin, 5-HT2A - genetics ; Risk factors ; Schizophrenia ; Schizophrenia - diagnostic imaging ; Schizophrenia - genetics ; Schizotypal Personality Disorder - diagnostic imaging ; Schizotypal Personality Disorder - genetics</subject><ispartof>Psychopharmacologia, 2008-01, Vol.195 (4), p.579-590</ispartof><rights>Springer-Verlag 2007</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</citedby><cites>FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-007-0921-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-007-0921-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19946450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17899021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hurlemann, René</creatorcontrib><creatorcontrib>Matusch, Andreas</creatorcontrib><creatorcontrib>Kuhn, Kai-Uwe</creatorcontrib><creatorcontrib>Berning, Julia</creatorcontrib><creatorcontrib>Elmenhorst, David</creatorcontrib><creatorcontrib>Winz, Oliver</creatorcontrib><creatorcontrib>Kolsch, Heike</creatorcontrib><creatorcontrib>Zilles, Karl</creatorcontrib><creatorcontrib>Wagner, Michael</creatorcontrib><creatorcontrib>Maier, Wolfgang</creatorcontrib><creatorcontrib>Bauer, Andreas</creatorcontrib><title>5-HT2A receptor density is decreased in the at-risk mental state</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS). Objective To study the cerebral 5-HT 2A receptor (5-HT 2A R) in the ARMS with [ 18 F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm. Materials and methods We quantified the spatial distribution of 5-HT 2A R binding potential (BP 1 ′) in never-medicated subjects assigned to early ( n  = 6) and late ( n  = 8) prodromal states of schizophrenia relative to healthy controls ( n  = 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT 2A R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP 1 ′ due to between-group differences in genotype distributions. Results Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP 1 ′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP 1 ′ was present in subjects who subsequently converted to first-episode psychosis ( n  = 5), but absent in non-converters ( n  = 9). Between-group differences were not confounded by a differential distribution of SNP genotypes. Conclusion These results suggest a progressive reduction of cortical 5-HT 2A R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT 2A R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain - diagnostic imaging</subject><subject>Brain Mapping</subject><subject>Cerebral Cortex - diagnostic imaging</subject><subject>Dominance, Cerebral - physiology</subject><subject>Early Diagnosis</subject><subject>Female</subject><subject>Fluorine Radioisotopes</subject><subject>Genetic Markers - genetics</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Genotype &amp; phenotype</subject><subject>Humans</subject><subject>Ketanserin - analogs &amp; derivatives</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurosciences</subject><subject>Neurotransmitters</subject><subject>Original Investigation</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Positron-Emission Tomography</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Receptor, Serotonin, 5-HT2A - genetics</subject><subject>Risk factors</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnostic imaging</subject><subject>Schizophrenia - genetics</subject><subject>Schizotypal Personality Disorder - diagnostic imaging</subject><subject>Schizotypal Personality Disorder - genetics</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kMtKBDEQRYMoOj4-wI00gu6ieXYnO0V8geBG1yHJVGtrT_eYyoD-vRlmYEAwm9yizq0qLiHHnF1wxppLZExwSYukzApOv7fIhCspqGCN2CYTxqSkkmuzR_YRP1h5yqhdsscbY23xTsiVpg8v4rpKEGGex1RNYcAu_1QdFhkTeIRp1Q1VfofKZ5o6_KxmMGTfV5h9hkOy0_oe4Wj9H5DXu9uXmwf69Hz_eHP9RKOqdaZKBW1aJWIMtRbT1sQopNE6RO2FbxoNNjRBBq9VlEbF2stSKKFE8EGClwfkfDV3nsavBWB2sw4j9L0fYFygaxiz1tSygKd_wI9xkYZymxPc2IbXhhWIr6CYRsQErZunbubTj-PMLbN1q2zdUi6zdd_Fc7IevAgzmG4c6zALcLYGPEbft8kPscMNZ62qlV4uFysOS2t4g7S58P_tvwiWj9Q</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Hurlemann, René</creator><creator>Matusch, Andreas</creator><creator>Kuhn, Kai-Uwe</creator><creator>Berning, Julia</creator><creator>Elmenhorst, David</creator><creator>Winz, Oliver</creator><creator>Kolsch, Heike</creator><creator>Zilles, Karl</creator><creator>Wagner, Michael</creator><creator>Maier, Wolfgang</creator><creator>Bauer, Andreas</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>5-HT2A receptor density is decreased in the at-risk mental state</title><author>Hurlemann, René ; Matusch, Andreas ; Kuhn, Kai-Uwe ; Berning, Julia ; Elmenhorst, David ; Winz, Oliver ; Kolsch, Heike ; Zilles, Karl ; Wagner, Michael ; Maier, Wolfgang ; Bauer, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-44b58f42ccb652df8cc23855bc5a2a775e9b7b3ba54c384c6a33ba4242bab3ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain - diagnostic imaging</topic><topic>Brain Mapping</topic><topic>Cerebral Cortex - diagnostic imaging</topic><topic>Dominance, Cerebral - physiology</topic><topic>Early Diagnosis</topic><topic>Female</topic><topic>Fluorine Radioisotopes</topic><topic>Genetic Markers - genetics</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Genotype &amp; phenotype</topic><topic>Humans</topic><topic>Ketanserin - analogs &amp; derivatives</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurosciences</topic><topic>Neurotransmitters</topic><topic>Original Investigation</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Positron-Emission Tomography</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Receptor, Serotonin, 5-HT2A - genetics</topic><topic>Risk factors</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnostic imaging</topic><topic>Schizophrenia - genetics</topic><topic>Schizotypal Personality Disorder - diagnostic imaging</topic><topic>Schizotypal Personality Disorder - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hurlemann, René</creatorcontrib><creatorcontrib>Matusch, Andreas</creatorcontrib><creatorcontrib>Kuhn, Kai-Uwe</creatorcontrib><creatorcontrib>Berning, Julia</creatorcontrib><creatorcontrib>Elmenhorst, David</creatorcontrib><creatorcontrib>Winz, Oliver</creatorcontrib><creatorcontrib>Kolsch, Heike</creatorcontrib><creatorcontrib>Zilles, Karl</creatorcontrib><creatorcontrib>Wagner, Michael</creatorcontrib><creatorcontrib>Maier, Wolfgang</creatorcontrib><creatorcontrib>Bauer, Andreas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hurlemann, René</au><au>Matusch, Andreas</au><au>Kuhn, Kai-Uwe</au><au>Berning, Julia</au><au>Elmenhorst, David</au><au>Winz, Oliver</au><au>Kolsch, Heike</au><au>Zilles, Karl</au><au>Wagner, Michael</au><au>Maier, Wolfgang</au><au>Bauer, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5-HT2A receptor density is decreased in the at-risk mental state</atitle><jtitle>Psychopharmacologia</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>195</volume><issue>4</issue><spage>579</spage><epage>590</epage><pages>579-590</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>Rationale Current perspectives on the pathophysiology of schizophrenia direct attention to serotonergic (serotonin, 5-HT) dysregulation in the prodrome or at-risk mental state (ARMS). Objective To study the cerebral 5-HT 2A receptor (5-HT 2A R) in the ARMS with [ 18 F]altanserin positron emission tomography (PET) and a bolus-infusion paradigm. Materials and methods We quantified the spatial distribution of 5-HT 2A R binding potential (BP 1 ′) in never-medicated subjects assigned to early ( n  = 6) and late ( n  = 8) prodromal states of schizophrenia relative to healthy controls ( n  = 21). Five single nucleotide polymorphisms (SNPs) in the 5-HT 2A R-encoding gene (HTR2A; 13q14-21) were genotyped to control for a potential bias in BP 1 ′ due to between-group differences in genotype distributions. Results Group comparisons of partial-volume corrected PET data by statistical parametric mapping and confirmatory volume of interest analysis yielded a dissemination of BP 1 ′ decreases consistent with increasing levels of risk. An additional decrease in caudate BP 1 ′ was present in subjects who subsequently converted to first-episode psychosis ( n  = 5), but absent in non-converters ( n  = 9). Between-group differences were not confounded by a differential distribution of SNP genotypes. Conclusion These results suggest a progressive reduction of cortical 5-HT 2A R density as a surrogate biological measure of increased risk for schizophrenia, irrespective of conversion. Progressive reductions of subcortical 5-HT 2A R density could provide an indicator of illness activity and help to predict imminent conversion to schizophrenia. Moreover, our findings substantiate the rationale for establishing a phase-specific psychopharmacological intervention in the ARMS that addresses the serotonergic component of vulnerability to schizophrenia.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>17899021</pmid><doi>10.1007/s00213-007-0921-x</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacologia, 2008-01, Vol.195 (4), p.579-590
issn 0033-3158
1432-2072
language eng
recordid cdi_proquest_miscellaneous_70099863
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Adult
Adult and adolescent clinical studies
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Brain - diagnostic imaging
Brain Mapping
Cerebral Cortex - diagnostic imaging
Dominance, Cerebral - physiology
Early Diagnosis
Female
Fluorine Radioisotopes
Genetic Markers - genetics
Genetic Predisposition to Disease
Genotype
Genotype & phenotype
Humans
Ketanserin - analogs & derivatives
Male
Medical sciences
Neurosciences
Neurotransmitters
Original Investigation
Pharmacology
Pharmacology/Toxicology
Positron-Emission Tomography
Psychiatric Status Rating Scales
Psychiatry
Psychology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Receptor, Serotonin, 5-HT2A - genetics
Risk factors
Schizophrenia
Schizophrenia - diagnostic imaging
Schizophrenia - genetics
Schizotypal Personality Disorder - diagnostic imaging
Schizotypal Personality Disorder - genetics
title 5-HT2A receptor density is decreased in the at-risk mental state
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A21%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5-HT2A%20receptor%20density%20is%20decreased%20in%20the%20at-risk%20mental%20state&rft.jtitle=Psychopharmacologia&rft.au=Hurlemann,%20Ren%C3%A9&rft.date=2008-01-01&rft.volume=195&rft.issue=4&rft.spage=579&rft.epage=590&rft.pages=579-590&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/s00213-007-0921-x&rft_dat=%3Cproquest_cross%3E70099863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218971680&rft_id=info:pmid/17899021&rfr_iscdi=true